Mortality in cardiogenic shock is stronger associated to clinical factors than contemporary biomarkers reflecting neurohormonal stress and inflammatory activation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Mortality in cardiogenic shock is stronger associated to clinical factors than contemporary biomarkers reflecting neurohormonal stress and inflammatory activation. / Josiassen, Jakob; Frydland, Martin; Holmvang, Lene; Lerche Helgestad, Ole Kristian; Okkels Jensen, Lisette; Goetze, Jens Peter; Eifer Møller, Jacob; Hassager, Christian.

I: Biomarkers, Bind 25, Nr. 6, 09.2020, s. 506-512.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Josiassen, J, Frydland, M, Holmvang, L, Lerche Helgestad, OK, Okkels Jensen, L, Goetze, JP, Eifer Møller, J & Hassager, C 2020, 'Mortality in cardiogenic shock is stronger associated to clinical factors than contemporary biomarkers reflecting neurohormonal stress and inflammatory activation', Biomarkers, bind 25, nr. 6, s. 506-512. https://doi.org/10.1080/1354750X.2020.1795265

APA

Josiassen, J., Frydland, M., Holmvang, L., Lerche Helgestad, O. K., Okkels Jensen, L., Goetze, J. P., Eifer Møller, J., & Hassager, C. (2020). Mortality in cardiogenic shock is stronger associated to clinical factors than contemporary biomarkers reflecting neurohormonal stress and inflammatory activation. Biomarkers, 25(6), 506-512. https://doi.org/10.1080/1354750X.2020.1795265

Vancouver

Josiassen J, Frydland M, Holmvang L, Lerche Helgestad OK, Okkels Jensen L, Goetze JP o.a. Mortality in cardiogenic shock is stronger associated to clinical factors than contemporary biomarkers reflecting neurohormonal stress and inflammatory activation. Biomarkers. 2020 sep;25(6):506-512. https://doi.org/10.1080/1354750X.2020.1795265

Author

Josiassen, Jakob ; Frydland, Martin ; Holmvang, Lene ; Lerche Helgestad, Ole Kristian ; Okkels Jensen, Lisette ; Goetze, Jens Peter ; Eifer Møller, Jacob ; Hassager, Christian. / Mortality in cardiogenic shock is stronger associated to clinical factors than contemporary biomarkers reflecting neurohormonal stress and inflammatory activation. I: Biomarkers. 2020 ; Bind 25, Nr. 6. s. 506-512.

Bibtex

@article{4ca40ebab6044fb783b3377646739867,
title = "Mortality in cardiogenic shock is stronger associated to clinical factors than contemporary biomarkers reflecting neurohormonal stress and inflammatory activation",
abstract = "PURPOSE: To validate the IABP-SHOCK II risk score in a Danish cohort and assess the association between the IABP-SHOCK II risk score and admission concentration of biomarkers reflecting neurohormonal - (Copeptin, Pro-atrial natriuretic peptide (proANP), Mid-regional pro-adrenomedullin (MRproADM)) and inflammatory (ST2) activation in patients with CS complicating ST segment elevation myocardial infarction (STEMI).METHODS: A total of 137 consecutive patients admitted with STEMI and CS at two tertiary heart centres were stratified according to the IABP-SHOCK II risk score (0-2; 3/4; 5-9), and had blood sampled upon admission.RESULTS: Plasma concentrations of Copeptin (median (pmol/L) score 0-2: 313; score 3/4: 682; score 5-9: 632 p < 0.0001), proANP (pmol/L) (1459; 2225; 2876 p = 0.0009) and MRproADM (nmol/L) (0.86; 1.2; 1.4 p = 0.04) were significantly associated with the risk score, whereas ST2 (ng/mL) was not (44; 60; 45 p = 0.23). The IABP-SHOCK II risk score predicted 30-day mortality (score 0-2: 22%; score 4/3: 51%; score 5-9: 72%, area under the curve (AUC): 0.73, plogrank < 0.0001), while the tested biomarkers did not (AUC: 0.51CONCLUSION: Plasma concentrations of Copeptin, MRproADM and proANP were associated with the IABP-SHOCK II risk score in STEMI patients admitted with CS. The risk score predicted 30-day mortality, with no improvement in prediction when concentrations of the assessed biomarkers were added.",
author = "Jakob Josiassen and Martin Frydland and Lene Holmvang and {Lerche Helgestad}, {Ole Kristian} and {Okkels Jensen}, Lisette and Goetze, {Jens Peter} and {Eifer M{\o}ller}, Jacob and Christian Hassager",
year = "2020",
month = sep,
doi = "10.1080/1354750X.2020.1795265",
language = "English",
volume = "25",
pages = "506--512",
journal = "Biomarkers",
issn = "1354-750X",
publisher = "Taylor & Francis",
number = "6",

}

RIS

TY - JOUR

T1 - Mortality in cardiogenic shock is stronger associated to clinical factors than contemporary biomarkers reflecting neurohormonal stress and inflammatory activation

AU - Josiassen, Jakob

AU - Frydland, Martin

AU - Holmvang, Lene

AU - Lerche Helgestad, Ole Kristian

AU - Okkels Jensen, Lisette

AU - Goetze, Jens Peter

AU - Eifer Møller, Jacob

AU - Hassager, Christian

PY - 2020/9

Y1 - 2020/9

N2 - PURPOSE: To validate the IABP-SHOCK II risk score in a Danish cohort and assess the association between the IABP-SHOCK II risk score and admission concentration of biomarkers reflecting neurohormonal - (Copeptin, Pro-atrial natriuretic peptide (proANP), Mid-regional pro-adrenomedullin (MRproADM)) and inflammatory (ST2) activation in patients with CS complicating ST segment elevation myocardial infarction (STEMI).METHODS: A total of 137 consecutive patients admitted with STEMI and CS at two tertiary heart centres were stratified according to the IABP-SHOCK II risk score (0-2; 3/4; 5-9), and had blood sampled upon admission.RESULTS: Plasma concentrations of Copeptin (median (pmol/L) score 0-2: 313; score 3/4: 682; score 5-9: 632 p < 0.0001), proANP (pmol/L) (1459; 2225; 2876 p = 0.0009) and MRproADM (nmol/L) (0.86; 1.2; 1.4 p = 0.04) were significantly associated with the risk score, whereas ST2 (ng/mL) was not (44; 60; 45 p = 0.23). The IABP-SHOCK II risk score predicted 30-day mortality (score 0-2: 22%; score 4/3: 51%; score 5-9: 72%, area under the curve (AUC): 0.73, plogrank < 0.0001), while the tested biomarkers did not (AUC: 0.51CONCLUSION: Plasma concentrations of Copeptin, MRproADM and proANP were associated with the IABP-SHOCK II risk score in STEMI patients admitted with CS. The risk score predicted 30-day mortality, with no improvement in prediction when concentrations of the assessed biomarkers were added.

AB - PURPOSE: To validate the IABP-SHOCK II risk score in a Danish cohort and assess the association between the IABP-SHOCK II risk score and admission concentration of biomarkers reflecting neurohormonal - (Copeptin, Pro-atrial natriuretic peptide (proANP), Mid-regional pro-adrenomedullin (MRproADM)) and inflammatory (ST2) activation in patients with CS complicating ST segment elevation myocardial infarction (STEMI).METHODS: A total of 137 consecutive patients admitted with STEMI and CS at two tertiary heart centres were stratified according to the IABP-SHOCK II risk score (0-2; 3/4; 5-9), and had blood sampled upon admission.RESULTS: Plasma concentrations of Copeptin (median (pmol/L) score 0-2: 313; score 3/4: 682; score 5-9: 632 p < 0.0001), proANP (pmol/L) (1459; 2225; 2876 p = 0.0009) and MRproADM (nmol/L) (0.86; 1.2; 1.4 p = 0.04) were significantly associated with the risk score, whereas ST2 (ng/mL) was not (44; 60; 45 p = 0.23). The IABP-SHOCK II risk score predicted 30-day mortality (score 0-2: 22%; score 4/3: 51%; score 5-9: 72%, area under the curve (AUC): 0.73, plogrank < 0.0001), while the tested biomarkers did not (AUC: 0.51CONCLUSION: Plasma concentrations of Copeptin, MRproADM and proANP were associated with the IABP-SHOCK II risk score in STEMI patients admitted with CS. The risk score predicted 30-day mortality, with no improvement in prediction when concentrations of the assessed biomarkers were added.

U2 - 10.1080/1354750X.2020.1795265

DO - 10.1080/1354750X.2020.1795265

M3 - Journal article

C2 - 32649233

VL - 25

SP - 506

EP - 512

JO - Biomarkers

JF - Biomarkers

SN - 1354-750X

IS - 6

ER -

ID: 250554548